Search
Invasive meningococcal disease (IMD) causes significant morbidity and mortality worldwide with serogroup B being the predominant serogroup in Australia and other countries for the past few decades. The licensed 4CMenB vaccine is effective in preventing meningococcal B disease. Emerging evidence suggests that although 4CMenB impact on carriage is limited, it may be effective against gonorrhoea due to genetic similarities between Neisseria meningitidis and Neisseria gonorrhoeae.
Citation: Reid A, Bowen AC, Brennan-Jones CG, Kuthubutheen JB. Congenital cytomegalovirus: the case for targeted infant screening in Australia. Med J
BCG vaccination modulates immune responses to unrelated pathogens. This off-target effect could reduce the impact of emerging pathogens. As a readily available, inexpensive intervention that has a well-established safety profile, BCG is a good candidate for protecting healthcare workers (HCWs) and other vulnerable groups against COVID-19.
Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.
To generate a conceptual framework describing what is done to reduce the impact of chronic tinnitus on the lives of children and adolescents.
Chris Peter Brennan-Jones Richmond PhD MBBS MRCP(UK) FRACP Head, Ear and Hearing Health Head, Vaccine Trials Group chris.brennan-jones@thekids.org.au
Chris Brennan-Jones PhD Head, Ear and Hearing Health chris.brennan-jones@thekids.org.au Head, Ear and Hearing Health Professor Chris Brennan-Jones is
Chris Deborah Peter Tanisha Greta Karina Brennan-Jones Lehmann Richmond Cayley Bernabei Tao PhD AO, MBBS, MSc MBBS MRCP(UK) FRACP BBiomed (Hons) BSc
Deborah Peter Lehmann Richmond AO, MBBS, MSc MBBS MRCP(UK) FRACP Honorary Emeritus Fellow Head, Vaccine Trials Group Honorary Emeritus Fellow Head,
Otitis media (OM) is the leading cause of childhood hearing loss but its burden in low-middle-income countries like Papua New Guinea (PNG) is poorly understood. We aimed to determine the proportion of children aged ≤15 years attending clinics in Goroka, Eastern Highlands Province, PNG with OM and associated risk factors.